Skip to Content

'
Ana Aparicio, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3512
Phone: (713) 792-2830
Fax: (713) 745-1625

Education & Training

Degree-Granting Education

1995 Universidad Autónoma de Madrid, Madrid, Spain, MD, Medicine

Postgraduate Training

7/2000-7/2003 Medical Oncology and Hematology Fellowship, Medical Oncology and Hematology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Keck School of Medicine, Los Angeles, CA
6/1997-6/2000 Clinical Internship, Internal Medicine, West Los Angeles VA Medical Center, UCLA School of Medicine,, Los Angeles, CA
4/1996-4/1997 Clinical Residency, Medical Oncology, Hospital Universitario Doce de Octubre, Universidad Complutense de Madrid,, Madrid, Spain

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2013
Assistant Professor, Department of Medicine, Division of Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2004-2006
Clinical Instructor,, Department of Medicine, Division Medical Oncology, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA, 2003-2004

Other Appointments/Responsibilities

Regular Faculty Member, Member of The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2007-2012

Institutional Committee Activities

Associate Member, Institutional Review Board (IRB1), 2012-present
Reviewer, Clinical Research Committee (CRC3), 2009-2011

Honors and Awards

2002 Chief Fellow, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2002 Outstanding Fellow of the Year, USC/Norris Comprehensive Cancer Center, LAC Medical Center, Los Angeles, CA
2000 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1998 Solomon Scholars Award for Outstanding Research During Residency, UCLA School of Medicine
1992 Erasmus Scholarship, Granted by the European Community for Academic Excellence

Selected Publications

Peer-Reviewed Original Research Articles

1. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM.. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer pii: S1558-7673(14)00234-1. e-Pub 10/2014. PMID: 25465491.
2. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014). Sci Transl Med 6(252):252ra122, 9/2014. PMID: 25186177.
3. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. e-Pub 8/2014. PMID: 25155428.
4. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846-50, 6/2014. e-Pub 4/2014. PMCID: PMC4040316.
5. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. e-Pub 5/2014. PMCID: PMC4247811.
6. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-Ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 5/2014. PMCID: PMC4135429.
7. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/2013. PMCID: PMC3926428.
8. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
9. Goldkorn A, Aparicio AM, Quinn DI. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol 24(7):1717-20, 7/2013. PMID: 23798673.
10. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/2012. PMCID: PMC3882163.
11. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3):895-903, 3/2012. e-Pub 1/2012. PMID: 22245216.
12. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling lethal prostate cancer variant with small cell carcinoma features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMCID: PMC3923417.
13. Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 7(11):e48787, 2012. e-Pub 11/2012. PMCID: PMC3511501.
14. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol 29(6):682-9, Nov-Dec, 11/2011. e-Pub 12/2009. PMID: 19959380.
15. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov 1(6):466-8, 11/2011. PMCID: PMC4133693.
16. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 8(10):562-8, 10/2011. e-Pub 8/2011. PMCID: PMC3641817.
17. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical and gene expression profiles. Prostate 71(8):846-56, 6/2011. e-Pub 11/2010. PMCID: PMC3883511.
18. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol 34(1):27-31, 2/2011. e-Pub 2/2010. PMID: 20142723.
19. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 1/2011. e-Pub 10/2010. PMID: 21040948.
20. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer 2011:580318, 2011. e-Pub 11/2011. PMCID: PMC3236424.
21. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/2010. PMID: 19862815.
22. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. e-Pub 7/2009. PMCID: PMC2731785.
23. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate:clinical features and implications after local therapy. Cancer 115(13):2872-80, 7/2009. PMID: 19402048.
24. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3):176-84, 4/2009. e-Pub 4/2009. PMCID: PMC2848123.
25. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 4(2):48, 2009. e-Pub 8/2009. PMCID: PMC2731785.
26. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14(21):7138-42, 11/2008. PMCID: PMC3543872.
27. Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR, Asmar L, von Hoff DD. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Genitourin Cancer 14(21):7138-42, 12/2007. PMID: 18272030.
28. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 67(1):346-53, 1/2007. PMID: 17210717.
29. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457-63, 5/2004. PMID: 15164071.
30. Aparicio A, Eads C, Leong L, Laird PW, Newman N, Weber JS. Phase I trial of continuous infusion 5-Aza-2'-deoxyctidine (DAC). Cancer Chemother Pharmacol 51(3):231-39, 3/2003. PMID: 12655442.
31. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2):220-29, 2/1998. PMID: 9519785.
32. Tannir N, Plimack E, Ng, C, Pheroze T, Neby B, Lianchun X, Smith L, Zita L, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood C, Jonasch E. Tumor heterogeneity is reflected in the response of advance non-clear cell renal cell carcinomato sunitinib therapy. J Clin Oncol. Submitted.

Invited Articles

1. Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncol 7(3)(3):447-63, 3/2011. PMID: 21417907.
2. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7(5)(5):309-12, 3/2006. PMID: 16640801.
3. Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am 32(2):217-30, 5/2005. PMID: 15862619.
4. Aparicio A, Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-35, 5/2002. PMID: 11937001.
5. Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3(4):627-33, 4/2002. PMID: 12090735.
6. Weber JS, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13(2):124-28, 3/2001. PMID: 11224710.

Editorials

1. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol 65(6):1067-8, 6/2014. e-Pub 12/2013. PMID: 24411278.
Other Articles
1. Aparicio AM. Prostate Cancer: Clinical practitioner perspective. Endocrine News, 9/2011.

Abstracts

1. Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology (Williston Park) 15(28):10, 2014 Oct, 10/2014. PMID: 25323607.
2. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32 (#e16046), 2014.
3. Aparicio A, Maity S, Wang X, Hoang AG, Efstathiou E, Troncoso P, Logothetis CJ,. A molecular characterization of the anaplastic prostate carcinomas. 2013 AACR Annual Conference (#7587), 4/2013.
4. Aparicio A, Gallichotte E, Cheng H, Yoo SY, Maity S, Logothetis CJ, Tewari M,. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. 2013 AACR Annual Conference (#5692), 4/2013.
5. Kleb BN, Estecio M, Wu G, Lu JF, Logothetis CJ, Maity S, Aparicio A. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. 2013 AACR Annual Conference (#6786), 4/2013.
6. Quinn DI, Hamid O, Tsao-Wei D, Hu J, Pinski J, Schuckerman A, Daneshmand S, Groshen S, Raghaven D, Korn C, Massopust K, Ketchens C, Aparicio AM, Dorff TB. Gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (PTS) with refractory germ cell carcinoma: A phase II study conducted at the University of Southern California. Ann Oncol 23(9):ix258-ix293 (#790O), 10/2012.
7. Aparicio A, Sun, J, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Radtke A, Sharma P,. A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma. Cancer Research 72(6) (#5368), 4/2012.
8. Kleb B, Estecio M, Zhang J, Tzelepi V, Chung, W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Aparicio A. The DNA methylome of castration-resistant prostate cancer. Cancer Research 72(6) (#991), 4/2012.
9. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29 (#4666), 6/2011.
10. Tzeelpi V, Maity S, Zhang J, Liang S, Lu JF, Anh H, Kleb B, Efstathiou E, Navone N, Troncoso P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. Cancer Research 71(8):10.1158/1538-7445.AM2011-36 (#36), 4/2011.
11. Tzelepi V, Maity S, Zhang J, Karlou M, Liang S, Hoang A, Lu J, Kleb B, Efstathiou E, Navone N, Aparicio A, Troncoso P. Differential expression of UBE2C and ASCL1 in neuroendocrine carcinoma and adenocarcinoma of the prostate in xenograft models and human samples. USCAP Annual Meeting, San Antonio, TX, 2011.
12. Efstathiou E, Tu S, Aparicio A, Hoang A, Troncoso P, Smith L, Chieffo N, Molina A, Logothetis C,. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate(AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(15s) (#4547), 2010.
13. Jonasch E, Wood G, Matin S, Tamboli K, Do L, Pagliaro C, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s (#5104), 5/2008.
14. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC). J Clin Oncol 26(15S):271s (#16000), 5/2008.
15. Ramalingam S, Parise RA, Egorin MJ, Argiris A, Stoller R, Beattie l, Aparicio A, Newman EM, Zwiebel J, Belani CP. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI # 6922). J Clin Oncol 24(18S) (#2077), 2006.
16. Dorff TB, Rupani R, Wei DT, Groshen S, Pinski J, Raghavan D, Quinn D, A. POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience. J Clin Oncol 24(18S) (#4591), 2006.
17. Egger G, Aparicio A, Escobar S, Jones PA. Effects of combinatiorial treatment of T24 cells with 5-aza-2' deoxycytidine and 4-phenylbutyric acid. AACR 96th Annual Meeting Proceedings Vol 46 (#1819), 2005.
18. Maity S, Wu G, Lu JF, Hoang A, Landesman Y, McCauley D, Carlson R, Rashal T, Shacham S, Broom B, Baggerly KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis CJ. Selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE) regulates tumor suppressors and cell cycle proteins in prostate cancer cells and induces regression of castration-resistant patient-derived xenograft tumor growth. ASCO 2015 Genitourinary Cancers Symposium (#141683). Submitted.

Book Chapters

1. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasm of the Prostate. In: Cancer Medicine, 8th. People Medical Publishing House-USA: Shelton, CONN, 1228-1254, 2010.
2. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA, 2009.

Grant & Contract Support

Title: Prostate Cancer Moonshot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer Flagship Project 2: Adaptive Androgen Signaling in mCRPC Effectively Targted by Novel Androgen Signaling Inhibitors
Funding Source: U.T. MD Anderson Moonshot Program
Role: FP2 Subproject Leader
Duration: 9/1/2014 - 8/31/2015
 
Title: Reprogramming Small Cell Prostate Carcinomas Through Ezh2 Inhibition To Develop Novel Therapeutic Strategies For Lethal Prostate Cancer
Funding Source: Institutional Research Grant (IRG)
Role: Principal Investigator
Duration: 1/1/2014 - 1/1/2015
 
Title: Reprogramming Small Cell Prostate Carcinomas Through EHZ2 Inhibitor to Develop Novel Therapeutic Strategies for Lethal Prostate Cancer
Funding Source: Center of Cancer Epigenetics (CCE) Pilot Project
Role: Principal Investigator
Duration: 9/1/2013 - 8/31/2014
 
Title: Reprogramming Small Cell Prostate Carcinomas Through EZH2 Inhibition To Develop Novel Therapeutic Strategies For Lethal Prostate Cancer
Funding Source: GlaxoSmithKline LLC
Role: Principal Investigator
Duration: 6/6/2013 - 6/30/2016
 
Title: Reprogramming Small Cell Prostate Carcinomas Through EZH2 Inhibition
Funding Source: GAP
Role: Principal Investigator
Duration: 2013
 
Title: Immunologic Checkpoint Blockage and Adoptive Cell Transfer in Cancer Therapy
Funding Source: American Association for Cancer Research (AACR)
Role: Young Investigator
Principal Investigator: Allison
Duration: 10/1/2012 - 9/30/2015
 
Title: PC1208632-Is the Mitotic Program a Driver of Androgen-Independent Prostate Cancer
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 2012
 
Title: Targeting Resistance to Androgen Depletion with the Aurora-A-Kinase Inhibitor Alisertib (MLN8237) in ANAPLASTIC Prostate Carcinomas
Funding Source: Prostate Cancer Foundation (PCF)
Role: Principal Investigator
Duration: 2012
 
Title: Early Identification of Castrate-Resistant Progression in the Primary Tumor of Men
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 2011
 
Title: Loss of RB and REST/NRSF Tumor Suppressor Functions in the Pathogenesis of Small Cell Prostate Cancer
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Duration: 2011
 
Title: Characterizing the Anaplastic Prostate Carcinomas
Funding Source: Texas Foundation Business Professional Women (TFBPW)
Role: Award Recipient
Duration: 2/2010
 
Title: Characterization of the Anaplastic Prostate Carcinomas
Funding Source: NIH-Spore-CDA
Role: Principal Investigator
Duration: 1/8/2010 - 8/31/2012
 
Title: Biomarkers of Epigenetic Therapy
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2010
 
Title: Biologic Markers of Activity in Epigenetic Therapy in a Phase I Trial of Low Doses of Decitabine with Oral Sodium Phenylbutyrate in Patients with Solid Tumors
Funding Source: Wright Foundation
Role: Principal Investigator
Duration: 7/8/2004 - 6/30/2005
 
Title: Pilot Study of Biomaker of Epigenetic Therapy in Peripheral Blood and Oral Mucosa Cells, Seed Grant Award
Funding Source: Institutional Research Grant (IRG)
Role: Principal Investigator
Duration: - 11/19/2004

Last updated: 12/10/2014